Distribution of trans-resveratrol and its metabolites after acute or sustained administration in mouse heart, brain, and liver

Molecular Nutrition and Food Research

Volumn 61, Issue 8, 2017, Pages

  Menet, Marie Claude ^a,b   Baron, Stephanie ^c,d   Taghi, Meryam ^a   Diestra, Remi ^c   Dargère, Delphine ^e   Laprévote, Olivier ^e   Nivet Antoine, Valérie ^c,f   Beaudeux, Jean Louis ^f,g   Bédarida, Tatiana ^c   Cottart, Charles Henry ^c,f,h  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e CNRS   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g National Institute of Health Medical Research)   (France)

^h INSTITUT NECKER ENFANTS MALADES   (France)

Author keywords

Administration; Distribution; Metabolites; Mice; Resveratrol

Indexed keywords

DIHYDRORESVERATROL; GLUCURONIDE; RESVERATROL; RESVERATROL-4'-O-GLUCURONIDE; STILBENE DERIVATIVE;

ANIMAL; BRAIN; DRUG EFFECT; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; MASS SPECTROMETRY; METABOLISM; MOUSE; PROCEDURES; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONIDES; HEART; LIVER; MASS SPECTROMETRY; MICE; STILBENES; TISSUE DISTRIBUTION;

EID: 85017378650     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201600686     Document Type: Article

References (49)

1. Timmer, S., Auwerx, J., Schrauwen, P., The journey of resveratrol from yeast to human. Aging 2012, 4, 146–158.
2. Novelle, M. G., Wahl, D., Dieguez, C., Bernier, M. et al., Resveratrol supplementation: where are we now and where should we go? Ageing Res. Rev. 2015, 21, 1–15.
3. Richard, T., Pawlus, A. D., Iglesias, M. L., Pedrot, E. et al., Neuroprotective properties of resveratrol and derivatives. Ann. N. Y. Acad. Sci. 2011, 1215, 103–108.
4. Petrovski, G., Gurusamy, N., Das, D. K., Resveratrol in cardiovascular health and disease. Ann. N. Y. Acad. Sci. 2011, 1215, 22–33.
5. Szkudelski, T., Szkudelska, K., Anti-diabetic effects of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215, 34–39.
6. Wenzel, E., Somoza, V., Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 2005, 49, 472–481.
7. Smoliga, J. M., Blanchard, O., Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution? Molecules 2014, 19, 17154–17172.
8. Walle, T., Bioavailability of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215, 9–15.
9. Aires, V., Delmas, D., Le Bachelier, C., Latruffe, N. et al., Stilbenes and resveratrol metabolites improve mitochondrial fatty acid oxidation defects in human fibroblasts. Orphanet J. Rare Dis. 2014, 9, 79.
10. Schueller, K., Pignitter, M., Somoza, V., Sulfated and glucuronated trans-resveratrol metabolites regulate chemokines and sirtuin-1 expression in u-937 macrophages. J. Agric. Food Chem. 2015, 63, 6535–6545.
11. Lu, D. L., Ding, D. J., Yan, W. J., Li, R. R. et al., Influence of glucuronidation and reduction modifications of resveratrol on its biological activities. Chembiochem 2013, 14, 1094–1104.
12. Cottart, C. H., Nivet-Antoine, V., Beaudeux, J. L., Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol. Nutr. Food Res. 2014, 58, 7–21.
13. Cottart, C. H., Nivet-Antoine, V., Laguillier-Morizot, C., Beaudeux, J. L., Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 2010, 54, 7–16.
14. Menet, M. C., Cottart, C. H., Taghi, M., Nivet-Antoine, V. et al., Ultra high performance liquid chromatography-quadrupole-time of flight analysis for the identification and the determination of resveratrol and its metabolites in mouse plasma. Anal. Chim. Acta 2013, 761, 128–136.
15. Azorin-Ortuno, M., Yanez-Gascon, M. J., Pallares, F. J., Vallejo, F. et al., Pharmacokinetic study of trans-resveratrol in adult pigs. J. Agric. Food Chem. 2010, 58, 11165–11171.
16. Azorin-Ortuno, M., Yanez-Gascon, M. J., Vallejo, F., Pallares, F. J. et al., Metabolites and tissue distribution of resveratrol in the pig. Mol. Nutr. Food Res. 2011, 55, 1154–1168.
17. Muzzio, M., Huang, Z., Hu, S. C., Johnson, W. D. et al., Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs. J. Pharm. Biomed. Anal. 2012, 59, 201–208.
18. Burnett, K., Puschner, B., Ramsey, J. J., Lin, Y. et al., Lack of glucuronidation products of trans-resveratrol in plasma and urine of cats. J. Anim. Physiol. Anim. Nutr. 2016, doi: 10.1111/jpn.12524.
19. Kapetanovic, I. M., Muzzio, M., Huang, Z., Thompson, T. N. et al., Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 2011, 68, 593–601.
20. Menet, M. C., Marchal, J., Dal-Pan, A., Taghi, M. et al., Resveratrol metabolism in a non-human primate, the grey mouse lemur (Microcebus murinus), using ultra-high-performance liquid chromatography-quadrupole time of flight. PLoS One 2014, 9, e91932.
21. Boocock, D. J., Faust, G. E., Patel, K. R., Schinas, A. M. et al., Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1246–1252.
22. Vitrac, X., Desmouliere, A., Brouillaud, B., Krisa, S. et al., Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 2003, 72, 2219–2233.
23. Alfaras, I., Perez, M., Juan, M. E., Merino, G. et al., Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J. Agric. Food Chem. 2010, 58, 4523–4528.
24. Ponzo, V., Soldati, L., Bo, S., Resveratrol: a supplementation for men or for mice? J. Transl. Med. 2014, 12, 158.
25. Pearson, K. J., Baur, J. A., Lewis, K. N., Peshkin, L. et al., Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8, 157–168.
26. Barger, J. L., Kayo, T., Vann, J. M., Arias, E. B. et al., A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008, 3, e2264.
27. Camont, L., Cottart, C. H., Rhayem, Y., Nivet-Antoine, V. et al., Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions. Anal. Chim. Acta 2009, 634, 121–128.
28. Baron, S., Bedarida, T., Cottart, C. H., Vibert, F. et al., Dual effects of resveratrol on arterial damage induced by insulin resistance in aged mice. J. Gerontol. A. Biol. Sci. Med. Sci. 2014, 69, 260–269.
29. Baron, S., Cottart, C. H., Laguillier-Morizot, C., Marchiol, C. et al., Interest of a chronic resveratrol treatment in the pathophysiology of the arterial aging. Fundam. Clin. Pharmacol. 2010, 24, 141.
30. Bedarida, T., Baron, S., Vessieres, E., Vibert, F. et al., High protein–low carbohydrate diet: deleterious metabolic and cardiovascular effects depend on age. Am. J. Physiol. Heart Circ. Physiol. 2014, 307, H649–H657.
31. Juan, M. E., Maijo, M., Planas, J. M., Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J. Pharm. Biomed. Anal. 2010, 51, 391–398.
32. Shah, V. P., The history of bioanalytical method validation and regulation: evolution of a guidance document on bioanalytical methods validation. AAPS J. 2007, 9, E43–E47.
33. Sale, S., Verschoyle, R. D., Boocock, D., Jones, D. J. et al., Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene. Br. J. Cancer 2004, 90, 736–744.
34. Asensi, M., Medina, I., Ortega, A., Carretero, J. et al., Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 2002, 33, 387–398.
35. Ramalingam, P., Ko, Y. T., Validated LC-MS/MS method for simultaneous quantification of resveratrol levels in mouse plasma and brain and its application to pharmacokinetic and brain distribution studies. J. Pharm. Biomed. Anal. 2016, 119, 71–75.
36. Vitaglione, P., Sforza, S., Galaverna, G., Ghidini, C. et al., Bioavailability of trans-resveratrol from red wine in humans. Mol. Nutr. Food Res. 2005, 49, 495–504.
37. Goldberg, D. M., Yan, J., Soleas, G. J., Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 2003, 36, 79–87.
38. Desquiret-Dumas, V., Gueguen, N., Leman, G., Baron, S. et al., Resveratrol induces a mitochondrial complex I-dependent increase in NADH oxidation responsible for sirtuin activation in liver cells. J. Biol. Chem. 2013, 288, 36662–36675.
39. Gueguen, N., Desquiret-Dumas, V., Leman, G., Chupin, S. et al., Resveratrol directly binds to mitochondrial complex I and increases oxidative stress in brain Mitochondria of aged mice. PLoS One 2015, 10, e0144290.
40. Bresciani, L., Calani, L., Bocchi, L., Delucchi, F. et al., Bioaccumulation of resveratrol metabolites in myocardial tissue is dose-time dependent and related to cardiac hemodynamics in diabetic rats. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 408–415.
41. Marier, J. F., Vachon, P., Gritsas, A., Zhang, J. et al., Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 2002, 302, 369–373.
42. Bode, L. M., Bunzel, D., Huch, M., Cho, G. S. et al., In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am. J. Clin. Nutr. 2013, 97, 295–309.
43. Snipes, R. L., Anatomy of the cecum of the laboratory mouse and rat. Anat. Embryol. 1981, 162, 455–474.
44. Walker, J., Schueller, K., Schaefer, L. M., Pignitter, M. et al., Resveratrol and its metabolites inhibit pro-inflammatory effects of lipopolysaccharides in U-937 macrophages in plasma-representative concentrations. Food Funct. 2014, 5, 74–84.
45. Ladurner, A., Schachner, D., Schueller, K., Pignitter, M. et al., Impact of trans-resveratrol-sulfates and -glucuronides on endothelial nitric oxide synthase activity, nitric oxide release and intracellular reactive oxygen species. Molecules 2014, 19, 16724–16736.
46. Polycarpou, E., Meira, L. B., Carrington, S., Tyrrell, E. et al., Resveratrol 3-O-d-glucuronide and resveratrol 4′-O-d-glucuronide inhibit colon cancer cell growth: evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest. Mol. Nutr. Food Res. 2013, 57, 1708–1717.
47. Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W. et al., Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases–safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. 2011, 4, 1419–1425.
48. Bernier, M., Wahl, D., Ali, A., Allard, J. et al., Resveratrol supplementation confers neuroprotection in cortical brain tissue of nonhuman primates fed a high-fat/sucrose diet. Aging 2016, 8, 899–916.
49. Turner, R. S., Thomas, R. G., Craft, S., van Dyck, C. H. et al., A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology 2015, 85, 1383–1391.